PainChek [ASX:PCK] is exploring a new use in a COVID world.

When it comes to end-of-life care, knowing your loved one is not suffering is usually the greatest concern for friends and family.

This is significantly heightened at the moment with COVID-19 preventing many people from being with their loved ones leading up to and at their time of passing.

To alleviate this, PainChek is looking to use its smartphone pain management technology to provide a live stream update of the person's pain levels direct to a family members phone.

"What we realised is we have already got the technology to feed to carers but we are now looking at being able to loop in family members as well," Phillip Daffas, CEO of PainChek told me.

He said this live pain update concept was one of several changes the company has gone through amidst the pandemic.

"While it [pandemic] has pushed back our growth plans in many areas toward September, the changes we have needed to make during the pandemic will put us in a far stronger position when things start to open up.

"For example, we have taken our entire training system on line which will reap many productivity and cost gains going forward," he said.

[USE THE NEW CHAPTER OPTION TO JUMP DIRECTLY TO YOUR AREA OF INTEREST]

1. Day to day business life in a COVID world

2. Impact of COVID on PainChek growth plans

3. Homecare opportunities

4. Current cash/revenue

5. Progress on Phillips deal

6. Progress on children's app

DISCLAIMER AND IMPORTANT INFORMATION I do own shares in PainChek at the time of writing this post. However I do not accept any payment from this or any other companies I cover. Nor is my interview or blog in any way a recommendation and should not be seen as a form of financial advice. Disruptive technology stocks should be considered very speculative, high-risk, and extremely volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.